This post was originally published on this site
Novavax shares rose 7% after the report.
The EMA, WHO and Novavax did not immediately respond to requests for comment.
A WHO approval could come once the health body issued its own emergency use listing, or if the EMA gave it a conditional marketing authorisation, the newspaper reported.
